Key result
Long-term plozasiran sustains up to ~79% triglyceride reductions with ~74% adverse event incidence.
Why the study?
Long-term data suggested maintenance of triglyceride reductions beyond blinded treatment periods, supporting further evaluation of plozasiran across a broad spectrum of hypertriglyceridemia.
Does long-term open-label plozasiran (25 mg SC Q3M) maintain safety and sustained reductions in triglycerides and atherogenic lipoproteins over 24 months in adults with severe hypertriglyceridemia or mixed hyperlipidemia?
Does long-term open-label plozasiran (25 mg SC Q3M) maintain safety and sustained reductions in triglycerides and atherogenic lipoproteins over 24 months in adults with severe hypertriglyceridemia or mixed hyperlipidemia?
Long-term open-label plozasiran (25 mg quarterly) over 24 months demonstrated sustained triglyceride and ApoC-III reductions (-79% and -63% mean TG reduction at Month 24 in severe and moderate hypertriglyceridemia, respectively) with no acute pancreatitis events and a consistent safety profile.
Answers are grounded in this paper and cite their sources.
Sustained TG reductions seen in open-label extension; extends short-term data but leaves open randomized outcome trials.
Plozasiran, a hepatocyte-targeted siRNA against apolipoprotein C-III, has demonstrated substantial reductions in triglycerides (TGs) and related atherogenic lipoproteins across a spectrum of hypertriglyceridemia (HTG), leading to its approval for familial chylomicronemia syndrome in the United States, and subsequently in Canada and China. Long-term data suggest maintenance of these effects beyond the blinded treatment periods, supporting further evaluation of plozasiran across a broad spectrum of HTG. Safety and efficacy were assessed in this open-label extension (OLE) of two phase 2b, randomized, double-blind trials, SHASTA-2 ( n = 229) including patients with severe HTG (TG >500 mg/dL) and MUIR ( n = 353) including patients with mixed hyperlipidemia (TG 150–499 mg/dL, LDL-C ≥ 70 mg/dL or non-HDL-C ≥ 100 mg/dL). Participants initially received plozasiran at the assigned dose level in the randomized study before eventually transitioning to a regimen of 25 mg Q3M. Treatment-emergent adverse events (TEAEs), change in fasting TGs, and atherogenic lipoproteins were measured over a two-year follow-up. Plozasiran produced sustained TG reductions relative to baseline, over 24 months in the OLE. In SHASTA-2, mean TG reductions from baseline were -77% and -79% at Months 12 and 24, respectively, compared with -71%, at Month 6 of the index study (25 mg). In MUIR, reductions were -62% and -63%, versus -56% at Month 6, compared to baseline. Favorable effects were also observed for other secondary endpoints including remnant cholesterol, non-HDL-C, ApoB, HDL-C, and LDL-C. Common TEAEs included diabetes, COVID-19, upper respiratory tract infection, and back pain, consistent with prior studies; HbA1c levels remained stable. Long-term open-label treatment with plozasiran resulted in sustained TG reductions compared to baseline, across a broad range of HTG, with a safety profile consistent with earlier trials. (Funded by Arrowhead Pharmaceuticals, Inc.; ClinicalTrials.gov number NCT05413135)
No takes yet. Share an insight, caveat, or question.
Ballantyne et al. (2026) studied Severe hypertriglyceridemia (SHASTA-2) and mixed hyperlipidemia (MUIR) (n=418). Plozasiran vs. None in the open-label extension (all participants received open-label plozasiran, analyzed as prior placebo-to-plozasiran vs continuous plozasiran) was evaluated on Subject incidence of treatment-emergent adverse events (TEAEs) through end-of-study. Long-term open-label plozasiran resulted in a 74.2% incidence of treatment-emergent adverse events and sustained mean triglyceride reductions of 79% in SHASTA-2 and 63% in MUIR at 24 months.
Synapse has enriched 10 related papers. Consider them for comparative context: